Registry for Participants With Short Bowel Syndrome
Shire · Short Bowel Syndrome
Not applicable
Active, not recruiting
1,806
2025-10
Industry sponsor intelligence
ShireClinical Pipeline.
Lead-sponsor view of Shire's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 31
- Recruiting
- 0
- Active
- 1
- Completed
- 30
- Results posted
- 24
- Avg enrollment
- 55
Pipeline overview
Programs by phase and activity.
Velocity
Shire trials by start year
Study start year · indexed snapshot
Development
Trials by phase
28phase labels
Early Phase 10
Phase 15
Phase 22
Phase 321
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Teduglutide → | 21 | 4 | 2 | 14 | 0 | 1 |
| Icatibant → | 10 | 1 | 0 | 7 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
Shire · Short Bowel Syndrome
Phase 3
Completed
61
2025-03
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
Shire · Short Bowel Syndrome
Phase 3
Completed
29
2025-03
FIRAZYR General Drug Use-Results Survey (Japan)
Shire · Hereditary Angioedema (HAE)
Not applicable
Completed
179
2025-02
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)
Shire · Hereditary Angioedema (HAE)
Not applicable
Completed
1,761
2024-10
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
Shire · Healthy Volunteers
Phase 1
Completed
64
2022-10
A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302
Shire · Short Bowel Syndrome
Phase 3
Completed
9
2022-05
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
Shire · Short Bowel Syndrome
Phase 3
Completed
10
2022-02
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
Shire · Hereditary Angioedema
Phase 3
Completed
98
2021-06
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
Shire · Short Bowel Syndrome
Phase 3
Completed
88
2021-06
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Shire · Hereditary Angioedema
Phase 3
Completed
151
2021-06
Showing 10 of 30 studies
Search sponsor records
All Shire studies.
This page groups studies where Shire is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
31 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT01990040Registry for Participants With Short Bowel SyndromeOct 10, 2025NCT02954458Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)Mar 28, 2025NCT02949362Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 StudyMar 19, 2025NCT04057131FIRAZYR General Drug Use-Results Survey (Japan)Feb 21, 2025NCT01034969Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)Oct 28, 2024NCT04465396A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult ParticipantsOct 4, 2022NCT03268811A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302May 24, 2022NCT02980666Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral SupportFeb 2, 2022NCT00912093A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)Jun 11, 2021NCT00930644Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)Jun 11, 2021